CEO sold ~$2.43M of Quest Diagnostics
Scheduled in advanceLoading…
DGX · NYSE · Health Care Services
Health Care Services company based in Secaucus, New Jersey.
In the last 90 days, no insider of Quest Diagnostics reported an open-market purchase and 5 open-market sales worth about $8.32M. Members of Congress disclosed 5 trades in its stock. The latest 13F reports cover the quarter ending Jun 30, 2026. Every figure links to its official SEC, House, Senate or USAspending record.
Last closeLast close, Oct 5, 2026
$232.22
Last 12 months
+29.5%
Market value
$25.6B
S&P 500 +15.8% over the same dates. Prices adjusted for splits and dividends.
Bets against the stock: 3.6M shares sold short (3.3% of shares outstanding), +4.5% vs the previous count, 3.7 days of normal trading to buy them back. FINRA, as of Sep 15, 2026.
Revenue
$3.04B
+10.2% vs the same quarter a year earlier
Free cash flow, last 12 months
$1.35B
This quarter $459M, a year earlier $436M
Net debt
$5.02B
Debt $5.64B, cash $626M, at Jun 30, 2026
Net income, last 12 months
$1.06B
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Jul 23, 2026.
Insiders buying, last 90 days
None
No open-market purchases reported
Insiders selling, last 90 days
5 sales
$8.32M sold. Insiders sell for many reasons.
New federal contracts, 12 months
None
Nothing found for this company
Revenue, fiscal 2025
$11B
+11.8% vs the year before
Net income, fiscal 2025
$992M
As reported in the annual filing
Shares outstanding
110M
As of Jul 15, 2026
In fiscal 2025 the company spent $450M buying back its own shares and $353M on dividends. Cash actually paid, from its cash-flow statement.
CEO sold ~$2.43M of Quest Diagnostics
Scheduled in advanceOfficer sold ~$3.89M of Quest Diagnostics
Scheduled in advanceOfficer sold ~$1.52M of Quest Diagnostics
Scheduled in advanceThe holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
15 certified in FY2026 Q3, vs 11 a year earlier. 54 positions in total, median offered wage $81K a year.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
Vanguard Capital Management
Schedule 13G: passive · filed Apr 30, 2026 · 8.27M shares
Vanguard Portfolio Management
Schedule 13G: passive · filed Apr 29, 2026 · 6.1M shares
Anyone owning more than 5% must file within days. Structured filings exist since December 2024, so older stakes that were never amended may be missing.
Last 12 months, adjusted daily closes
Adjusted close went from $178.43 on Oct 6, 2025 to $232.22 on Oct 5, 2026 (+30.1%). Disclosed activity in the last 12 months: 0 insider purchases, 30 insider sales (28 under pre-arranged plans), 3 Congress purchases, 2 Congress sales, 1 fund report of opening or adding and 0 fund reports of trimming or selling out (13F, quarter-end snapshots).
Short sale volume: 58.4% of the volume reported to FINRA over the last 20 trading days was marked short, below its 1-year average of 61.1%. FINRA daily files, to Oct 5, 2026.
Short sale volume is not short interest. It counts trades marked short, including market makers selling short to fill buy orders, so it is a share of daily trading, not a count of bets against the stock.